Review



dcas13b adar2dd plasmid  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Addgene inc dcas13b adar2dd plasmid
    Dcas13b Adar2dd Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dcas13b+adar2dd+plasmid/pm41905718-67-1-3?v=Addgene+inc
    Average 93 stars, based on 10 article reviews
    dcas13b adar2dd plasmid - by Bioz Stars, 2026-07
    93/100 stars

    Images



    Similar Products

    dcas13b adar2dd plasmid  (Addgene inc)
    93
    Addgene inc dcas13b adar2dd plasmid
    Dcas13b Adar2dd Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dcas13b+adar2dd+plasmid/pm41905718-67-1-3?v=Addgene+inc
    Average 93 stars, based on 1 article reviews
    dcas13b adar2dd plasmid - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    psp dcas13b adar2dd e488q delta 984 1090  (Addgene inc)
    93
    Addgene inc psp dcas13b adar2dd e488q delta 984 1090
    50nt PspdCas13b sgRNA with Tiled A-C Mismatch Do Not Edit the Endogenous E198K site in patient-derived neural stem cells. (A) Amplicon sequencing results of the relative read number of wild-type (GAA) and E198K (AAA) reads in E198K NSCs transfected with sgRNA and <t>dPspCas13b--ADAR2DD(E488Q/T375G)-delta-984-1090</t> plasmid construct. (B) Amplicon sequencing results of E198K NSCs transfected with PPIB sgRNA and dPspCas13b--ADAR2DD(E488Q/T375G)-delta-984-1090 plasmid construct. Percent editing was determined as the number of edited transcript reads over not edited transcripts in the treated group and normalized to not-treated E198K NSCs. *significantly different from not treated E198K NSCs, t-test P < .05. (C-F) Amplicon sequencing results of percent editing of the E198K site in E198K NSCs following screen with sgRNA of increasing length and PspdCas13b-ADAR2DD constructs. Percent editing was determined as the number of edited transcript reads over not edited transcripts in treated group and normalized to not-treated E198K. * ** and **** significantly different from respective construct with no gRNA control, one-way ANOVA P < .05. (G—J) Amplicon sequencing results of percent editing of the E198K site in E198K NSCS following screen with sgRNA 190 and variable A-C mismatch position and PspdCas13b-ADAR2DD constructs. Percent editing was determined as the number of edited transcript reads over not edited transcripts in treated group and normalized to not-treated E198K. * ** and **** significantly different from respective construct with no gRNA control, one-way ANOVA P < .05.
    Psp Dcas13b Adar2dd E488q Delta 984 1090, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dcas13b+adar2dd+plasmid/pmc11811633-90-12-14?v=Addgene+inc
    Average 93 stars, based on 1 article reviews
    psp dcas13b adar2dd e488q delta 984 1090 - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    psp dcas13b adar2dd e488q t375g delta 984 1090  (Addgene inc)
    93
    Addgene inc psp dcas13b adar2dd e488q t375g delta 984 1090
    50nt PspdCas13b sgRNA with Tiled A-C Mismatch Do Not Edit the Endogenous E198K site in patient-derived neural stem cells. (A) Amplicon sequencing results of the relative read number of wild-type (GAA) and E198K (AAA) reads in E198K NSCs transfected with sgRNA and <t>dPspCas13b--ADAR2DD(E488Q/T375G)-delta-984-1090</t> plasmid construct. (B) Amplicon sequencing results of E198K NSCs transfected with PPIB sgRNA and dPspCas13b--ADAR2DD(E488Q/T375G)-delta-984-1090 plasmid construct. Percent editing was determined as the number of edited transcript reads over not edited transcripts in the treated group and normalized to not-treated E198K NSCs. *significantly different from not treated E198K NSCs, t-test P < .05. (C-F) Amplicon sequencing results of percent editing of the E198K site in E198K NSCs following screen with sgRNA of increasing length and PspdCas13b-ADAR2DD constructs. Percent editing was determined as the number of edited transcript reads over not edited transcripts in treated group and normalized to not-treated E198K. * ** and **** significantly different from respective construct with no gRNA control, one-way ANOVA P < .05. (G—J) Amplicon sequencing results of percent editing of the E198K site in E198K NSCS following screen with sgRNA 190 and variable A-C mismatch position and PspdCas13b-ADAR2DD constructs. Percent editing was determined as the number of edited transcript reads over not edited transcripts in treated group and normalized to not-treated E198K. * ** and **** significantly different from respective construct with no gRNA control, one-way ANOVA P < .05.
    Psp Dcas13b Adar2dd E488q T375g Delta 984 1090, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dcas13b+adar2dd+plasmid/pmc11811633-90-25-27?v=Addgene+inc
    Average 93 stars, based on 1 article reviews
    psp dcas13b adar2dd e488q t375g delta 984 1090 - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    psp dcas13b adar2dd  (Addgene inc)
    93
    Addgene inc psp dcas13b adar2dd
    Top DEGs are not rescued by <t>PspdCas13b-ADAR2DD</t> constructs and sgRNA 190. Relative expression of the 3 top DEGs between the isogenic and E198K NSC cell states in isogenic, not-treated E198K NSCs, E198K NSCs treated with Psp <t>dCas13b-ADAR2DD(E488Q),</t> Psp dCas13b-ADAR2DD(E488Q)-delta-984-1090, Psp <t>dCas13b-ADAR2DD(E488Q/T375G),</t> or Psp dCas13b-ADAR2DD(E488Q/T375G)-delta-984-1090. (A) RWDD28 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (B) ZNF717 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (C) CTSF relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05.
    Psp Dcas13b Adar2dd, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dcas13b+adar2dd+plasmid/pmc11811633-90-7-9?v=Addgene+inc
    Average 93 stars, based on 1 article reviews
    psp dcas13b adar2dd - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    dcas13b haddr2  (Addgene inc)
    93
    Addgene inc dcas13b haddr2
    Top DEGs are not rescued by <t>PspdCas13b-ADAR2DD</t> constructs and sgRNA 190. Relative expression of the 3 top DEGs between the isogenic and E198K NSC cell states in isogenic, not-treated E198K NSCs, E198K NSCs treated with Psp <t>dCas13b-ADAR2DD(E488Q),</t> Psp dCas13b-ADAR2DD(E488Q)-delta-984-1090, Psp <t>dCas13b-ADAR2DD(E488Q/T375G),</t> or Psp dCas13b-ADAR2DD(E488Q/T375G)-delta-984-1090. (A) RWDD28 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (B) ZNF717 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (C) CTSF relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05.
    Dcas13b Haddr2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dcas13b+adar2dd+plasmid/bio_rxiv__2022__01__25__477620-31-9-10?v=Addgene+inc
    Average 93 stars, based on 1 article reviews
    dcas13b haddr2 - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    50nt PspdCas13b sgRNA with Tiled A-C Mismatch Do Not Edit the Endogenous E198K site in patient-derived neural stem cells. (A) Amplicon sequencing results of the relative read number of wild-type (GAA) and E198K (AAA) reads in E198K NSCs transfected with sgRNA and dPspCas13b--ADAR2DD(E488Q/T375G)-delta-984-1090 plasmid construct. (B) Amplicon sequencing results of E198K NSCs transfected with PPIB sgRNA and dPspCas13b--ADAR2DD(E488Q/T375G)-delta-984-1090 plasmid construct. Percent editing was determined as the number of edited transcript reads over not edited transcripts in the treated group and normalized to not-treated E198K NSCs. *significantly different from not treated E198K NSCs, t-test P < .05. (C-F) Amplicon sequencing results of percent editing of the E198K site in E198K NSCs following screen with sgRNA of increasing length and PspdCas13b-ADAR2DD constructs. Percent editing was determined as the number of edited transcript reads over not edited transcripts in treated group and normalized to not-treated E198K. * ** and **** significantly different from respective construct with no gRNA control, one-way ANOVA P < .05. (G—J) Amplicon sequencing results of percent editing of the E198K site in E198K NSCS following screen with sgRNA 190 and variable A-C mismatch position and PspdCas13b-ADAR2DD constructs. Percent editing was determined as the number of edited transcript reads over not edited transcripts in treated group and normalized to not-treated E198K. * ** and **** significantly different from respective construct with no gRNA control, one-way ANOVA P < .05.

    Journal: Stem Cells

    Article Title: A de novo missense mutation in PPP2R5D alters dopamine pathways and morphology of iPSC-derived midbrain neurons

    doi: 10.1093/stmcls/sxae068

    Figure Lengend Snippet: 50nt PspdCas13b sgRNA with Tiled A-C Mismatch Do Not Edit the Endogenous E198K site in patient-derived neural stem cells. (A) Amplicon sequencing results of the relative read number of wild-type (GAA) and E198K (AAA) reads in E198K NSCs transfected with sgRNA and dPspCas13b--ADAR2DD(E488Q/T375G)-delta-984-1090 plasmid construct. (B) Amplicon sequencing results of E198K NSCs transfected with PPIB sgRNA and dPspCas13b--ADAR2DD(E488Q/T375G)-delta-984-1090 plasmid construct. Percent editing was determined as the number of edited transcript reads over not edited transcripts in the treated group and normalized to not-treated E198K NSCs. *significantly different from not treated E198K NSCs, t-test P < .05. (C-F) Amplicon sequencing results of percent editing of the E198K site in E198K NSCs following screen with sgRNA of increasing length and PspdCas13b-ADAR2DD constructs. Percent editing was determined as the number of edited transcript reads over not edited transcripts in treated group and normalized to not-treated E198K. * ** and **** significantly different from respective construct with no gRNA control, one-way ANOVA P < .05. (G—J) Amplicon sequencing results of percent editing of the E198K site in E198K NSCS following screen with sgRNA 190 and variable A-C mismatch position and PspdCas13b-ADAR2DD constructs. Percent editing was determined as the number of edited transcript reads over not edited transcripts in treated group and normalized to not-treated E198K. * ** and **** significantly different from respective construct with no gRNA control, one-way ANOVA P < .05.

    Article Snippet: Four available Psp dCas13b-ADAR2DD constructs were screened: Psp dCas13b-ADAR2DD(E488Q) (Addgene plasmid #103849), Psp dCas13b-ADAR2DD(E488Q)-delta-984-1090 (Addgene plasmid #103 869), Psp dCas13b-ADAR2DD(E488Q/T375G) (Addgene plasmid #103 870), and Psp dCas13b-ADAR2DD(E488Q/T375G)-delta-984-1090 (Addgene plasmid #103 871).

    Techniques: Derivative Assay, Amplification, Sequencing, Transfection, Plasmid Preparation, Construct, Control

    Top DEGs are not rescued by PspdCas13b-ADAR2DD constructs and sgRNA 190. Relative expression of the 3 top DEGs between the isogenic and E198K NSC cell states in isogenic, not-treated E198K NSCs, E198K NSCs treated with Psp dCas13b-ADAR2DD(E488Q), Psp dCas13b-ADAR2DD(E488Q)-delta-984-1090, Psp dCas13b-ADAR2DD(E488Q/T375G), or Psp dCas13b-ADAR2DD(E488Q/T375G)-delta-984-1090. (A) RWDD28 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (B) ZNF717 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (C) CTSF relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05.

    Journal: Stem Cells

    Article Title: A de novo missense mutation in PPP2R5D alters dopamine pathways and morphology of iPSC-derived midbrain neurons

    doi: 10.1093/stmcls/sxae068

    Figure Lengend Snippet: Top DEGs are not rescued by PspdCas13b-ADAR2DD constructs and sgRNA 190. Relative expression of the 3 top DEGs between the isogenic and E198K NSC cell states in isogenic, not-treated E198K NSCs, E198K NSCs treated with Psp dCas13b-ADAR2DD(E488Q), Psp dCas13b-ADAR2DD(E488Q)-delta-984-1090, Psp dCas13b-ADAR2DD(E488Q/T375G), or Psp dCas13b-ADAR2DD(E488Q/T375G)-delta-984-1090. (A) RWDD28 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (B) ZNF717 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (C) CTSF relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05.

    Article Snippet: Four available Psp dCas13b-ADAR2DD constructs were screened: Psp dCas13b-ADAR2DD(E488Q) (Addgene plasmid #103849), Psp dCas13b-ADAR2DD(E488Q)-delta-984-1090 (Addgene plasmid #103 869), Psp dCas13b-ADAR2DD(E488Q/T375G) (Addgene plasmid #103 870), and Psp dCas13b-ADAR2DD(E488Q/T375G)-delta-984-1090 (Addgene plasmid #103 871).

    Techniques: Construct, Expressing, Quantitative RT-PCR

    50nt PspdCas13b sgRNA with Tiled A-C Mismatch Do Not Edit the Endogenous E198K site in patient-derived neural stem cells. (A) Amplicon sequencing results of the relative read number of wild-type (GAA) and E198K (AAA) reads in E198K NSCs transfected with sgRNA and dPspCas13b--ADAR2DD(E488Q/T375G)-delta-984-1090 plasmid construct. (B) Amplicon sequencing results of E198K NSCs transfected with PPIB sgRNA and dPspCas13b--ADAR2DD(E488Q/T375G)-delta-984-1090 plasmid construct. Percent editing was determined as the number of edited transcript reads over not edited transcripts in the treated group and normalized to not-treated E198K NSCs. *significantly different from not treated E198K NSCs, t-test P < .05. (C-F) Amplicon sequencing results of percent editing of the E198K site in E198K NSCs following screen with sgRNA of increasing length and PspdCas13b-ADAR2DD constructs. Percent editing was determined as the number of edited transcript reads over not edited transcripts in treated group and normalized to not-treated E198K. * ** and **** significantly different from respective construct with no gRNA control, one-way ANOVA P < .05. (G—J) Amplicon sequencing results of percent editing of the E198K site in E198K NSCS following screen with sgRNA 190 and variable A-C mismatch position and PspdCas13b-ADAR2DD constructs. Percent editing was determined as the number of edited transcript reads over not edited transcripts in treated group and normalized to not-treated E198K. * ** and **** significantly different from respective construct with no gRNA control, one-way ANOVA P < .05.

    Journal: Stem Cells

    Article Title: A de novo missense mutation in PPP2R5D alters dopamine pathways and morphology of iPSC-derived midbrain neurons

    doi: 10.1093/stmcls/sxae068

    Figure Lengend Snippet: 50nt PspdCas13b sgRNA with Tiled A-C Mismatch Do Not Edit the Endogenous E198K site in patient-derived neural stem cells. (A) Amplicon sequencing results of the relative read number of wild-type (GAA) and E198K (AAA) reads in E198K NSCs transfected with sgRNA and dPspCas13b--ADAR2DD(E488Q/T375G)-delta-984-1090 plasmid construct. (B) Amplicon sequencing results of E198K NSCs transfected with PPIB sgRNA and dPspCas13b--ADAR2DD(E488Q/T375G)-delta-984-1090 plasmid construct. Percent editing was determined as the number of edited transcript reads over not edited transcripts in the treated group and normalized to not-treated E198K NSCs. *significantly different from not treated E198K NSCs, t-test P < .05. (C-F) Amplicon sequencing results of percent editing of the E198K site in E198K NSCs following screen with sgRNA of increasing length and PspdCas13b-ADAR2DD constructs. Percent editing was determined as the number of edited transcript reads over not edited transcripts in treated group and normalized to not-treated E198K. * ** and **** significantly different from respective construct with no gRNA control, one-way ANOVA P < .05. (G—J) Amplicon sequencing results of percent editing of the E198K site in E198K NSCS following screen with sgRNA 190 and variable A-C mismatch position and PspdCas13b-ADAR2DD constructs. Percent editing was determined as the number of edited transcript reads over not edited transcripts in treated group and normalized to not-treated E198K. * ** and **** significantly different from respective construct with no gRNA control, one-way ANOVA P < .05.

    Article Snippet: Four available Psp dCas13b-ADAR2DD constructs were screened: Psp dCas13b-ADAR2DD(E488Q) (Addgene plasmid #103849), Psp dCas13b-ADAR2DD(E488Q)-delta-984-1090 (Addgene plasmid #103 869), Psp dCas13b-ADAR2DD(E488Q/T375G) (Addgene plasmid #103 870), and Psp dCas13b-ADAR2DD(E488Q/T375G)-delta-984-1090 (Addgene plasmid #103 871).

    Techniques: Derivative Assay, Amplification, Sequencing, Transfection, Plasmid Preparation, Construct, Control

    Top DEGs are not rescued by PspdCas13b-ADAR2DD constructs and sgRNA 190. Relative expression of the 3 top DEGs between the isogenic and E198K NSC cell states in isogenic, not-treated E198K NSCs, E198K NSCs treated with Psp dCas13b-ADAR2DD(E488Q), Psp dCas13b-ADAR2DD(E488Q)-delta-984-1090, Psp dCas13b-ADAR2DD(E488Q/T375G), or Psp dCas13b-ADAR2DD(E488Q/T375G)-delta-984-1090. (A) RWDD28 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (B) ZNF717 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (C) CTSF relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05.

    Journal: Stem Cells

    Article Title: A de novo missense mutation in PPP2R5D alters dopamine pathways and morphology of iPSC-derived midbrain neurons

    doi: 10.1093/stmcls/sxae068

    Figure Lengend Snippet: Top DEGs are not rescued by PspdCas13b-ADAR2DD constructs and sgRNA 190. Relative expression of the 3 top DEGs between the isogenic and E198K NSC cell states in isogenic, not-treated E198K NSCs, E198K NSCs treated with Psp dCas13b-ADAR2DD(E488Q), Psp dCas13b-ADAR2DD(E488Q)-delta-984-1090, Psp dCas13b-ADAR2DD(E488Q/T375G), or Psp dCas13b-ADAR2DD(E488Q/T375G)-delta-984-1090. (A) RWDD28 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (B) ZNF717 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (C) CTSF relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05.

    Article Snippet: Four available Psp dCas13b-ADAR2DD constructs were screened: Psp dCas13b-ADAR2DD(E488Q) (Addgene plasmid #103849), Psp dCas13b-ADAR2DD(E488Q)-delta-984-1090 (Addgene plasmid #103 869), Psp dCas13b-ADAR2DD(E488Q/T375G) (Addgene plasmid #103 870), and Psp dCas13b-ADAR2DD(E488Q/T375G)-delta-984-1090 (Addgene plasmid #103 871).

    Techniques: Construct, Expressing, Quantitative RT-PCR

    Top DEGs are not rescued by PspdCas13b-ADAR2DD constructs and sgRNA 190. Relative expression of the 3 top DEGs between the isogenic and E198K NSC cell states in isogenic, not-treated E198K NSCs, E198K NSCs treated with Psp dCas13b-ADAR2DD(E488Q), Psp dCas13b-ADAR2DD(E488Q)-delta-984-1090, Psp dCas13b-ADAR2DD(E488Q/T375G), or Psp dCas13b-ADAR2DD(E488Q/T375G)-delta-984-1090. (A) RWDD28 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (B) ZNF717 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (C) CTSF relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05.

    Journal: Stem Cells

    Article Title: A de novo missense mutation in PPP2R5D alters dopamine pathways and morphology of iPSC-derived midbrain neurons

    doi: 10.1093/stmcls/sxae068

    Figure Lengend Snippet: Top DEGs are not rescued by PspdCas13b-ADAR2DD constructs and sgRNA 190. Relative expression of the 3 top DEGs between the isogenic and E198K NSC cell states in isogenic, not-treated E198K NSCs, E198K NSCs treated with Psp dCas13b-ADAR2DD(E488Q), Psp dCas13b-ADAR2DD(E488Q)-delta-984-1090, Psp dCas13b-ADAR2DD(E488Q/T375G), or Psp dCas13b-ADAR2DD(E488Q/T375G)-delta-984-1090. (A) RWDD28 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (B) ZNF717 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (C) CTSF relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05.

    Article Snippet: Four available Psp dCas13b-ADAR2DD constructs were screened: Psp dCas13b-ADAR2DD(E488Q) (Addgene plasmid #103849), Psp dCas13b-ADAR2DD(E488Q)-delta-984-1090 (Addgene plasmid #103 869), Psp dCas13b-ADAR2DD(E488Q/T375G) (Addgene plasmid #103 870), and Psp dCas13b-ADAR2DD(E488Q/T375G)-delta-984-1090 (Addgene plasmid #103 871).

    Techniques: Construct, Expressing, Quantitative RT-PCR